http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 13 Aug 2026 07:09:52 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Apogee+Therapeutics+Inc+%28APGE%29+PT+Raised+to+%24135+at+Truist+Securities/26916327.html Truist Securities analyst Danielle Brill raised the price target on Apogee Therapeutics Inc (NASDAQ: APGE) to $135.00 (from $81.00) while maintaining a Hold rating. http://www.streetinsider.com/Analyst+PT+Change/Apogee+Therapeutics+Inc+%28APGE%29+PT+Raised+to+%24135+at+Truist+Securities/26916327.html Thu, 13 Aug 2026 07:09:52 -0400 APGE http://www.streetinsider.com/Downgrades/BTIG+Downgrades+Apogee+Therapeutics+Inc+%28APGE%29+to+Neutral/26908368.html <p>BTIG analyst Julian Harrison downgraded Apogee Therapeutics Inc (NASDAQ: APGE) from Buy to Neutral.</p><p>The analyst comments "Following the APGE shareholder vote yesterday approving the APGE acquisition agreement by AbbVie (ABBV, Not Rated; $135.11/ sh corresponding to $10.9B in total equity valuation), we are downgrading APGE to NEUTRAL. We believe this was a thoughtful acquisition, as ABBV can leverage its existing dermatology channels and compete in atopic dermatitis beyond JAK inhibitors with APGE's zumilokibart (zumi). We expect zumilokibart could command strong use in atopic dermatitis owing to best-in-class efficacy, Q3M to Q6M maintenance dosing, and potential for asthma and eosinophilic esophagitis http://www.streetinsider.com/Downgrades/BTIG+Downgrades+Apogee+Therapeutics+Inc+%28APGE%29+to+Neutral/26908368.html Wed, 12 Aug 2026 06:06:54 -0400 APGE http://www.streetinsider.com/Analyst+Comments/BTIG+Downgrades+Apogee+Therapeutics+Inc+%28APGE%29+to+Neutral/26908368.html <p>BTIG analyst Julian Harrison downgraded Apogee Therapeutics Inc (NASDAQ: APGE) from Buy to Neutral.</p><p>The analyst comments "Following the APGE shareholder vote yesterday approving the APGE acquisition agreement by AbbVie (ABBV, Not Rated; $135.11/ sh corresponding to $10.9B in total equity valuation), we are downgrading APGE to NEUTRAL. We believe this was a thoughtful acquisition, as ABBV can leverage its existing dermatology channels and compete in atopic dermatitis beyond JAK inhibitors with APGE's zumilokibart (zumi). We expect zumilokibart could command strong use in atopic dermatitis owing to best-in-class efficacy, Q3M to Q6M maintenance dosing, and potential for asthma and eosinophilic esophagitis http://www.streetinsider.com/Analyst+Comments/BTIG+Downgrades+Apogee+Therapeutics+Inc+%28APGE%29+to+Neutral/26908368.html Wed, 12 Aug 2026 06:06:54 -0400 APGE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+07++Filed+by%3A+Harwin+Peter+Evan/26906332.html si-local-file:///var/storage/secattach/20260811/26906332.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+07++Filed+by%3A+Harwin+Peter+Evan/26906332.html Tue, 11 Aug 2026 16:31:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+07++Filed+by%3A+Harwin+Peter+Evan/26906332.html si-local-file:///var/storage/secattach/20260811/26906332.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+07++Filed+by%3A+Harwin+Peter+Evan/26906332.html Tue, 11 Aug 2026 16:31:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+11/26905424.html si-local-file:///var/storage/secattach/20260811/26905424.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+11/26905424.html Tue, 11 Aug 2026 16:01:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+11/26905424.html si-local-file:///var/storage/secattach/20260811/26905424.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+11/26905424.html Tue, 11 Aug 2026 16:01:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Apogee+Therapeutics%2C++++++For%3A+Jun+30/26894542.html si-local-file:///var/storage/secattach/20260810/26894542.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Apogee+Therapeutics%2C++++++For%3A+Jun+30/26894542.html Mon, 10 Aug 2026 07:53:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Apogee+Therapeutics%2C++++++For%3A+Jun+30/26894542.html si-local-file:///var/storage/secattach/20260810/26894542.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Apogee+Therapeutics%2C++++++For%3A+Jun+30/26894542.html Mon, 10 Aug 2026 07:53:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+10/26894285.html si-local-file:///var/storage/secattach/20260810/26894285.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+10/26894285.html Mon, 10 Aug 2026 07:20:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+10/26894285.html si-local-file:///var/storage/secattach/20260810/26894285.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+10/26894285.html Mon, 10 Aug 2026 07:20:00 -0400 APGE O.56046883 http://www.streetinsider.com/Press+Releases/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html <p align="center"><em>AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide</em></p> <p align="center"><em>Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year</em></p> <p align="justify">SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&amp;I) markets, today reported second http://www.streetinsider.com/Press+Releases/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html Mon, 10 Aug 2026 07:00:00 -0400 A.36747586 APGE O.00036564 O.56046883 http://www.streetinsider.com/Press+Releases/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html <p align="center"><em>AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide</em></p> <p align="center"><em>Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year</em></p> <p align="justify">SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&amp;I) markets, today reported second http://www.streetinsider.com/Press+Releases/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html Mon, 10 Aug 2026 07:00:00 -0400 A.36747586 APGE O.00036564 O.56046883 http://www.streetinsider.com/Press+Releases/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html <p align="center"><em>AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide</em></p> <p align="center"><em>Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year</em></p> <p align="justify">SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&amp;I) markets, today reported second http://www.streetinsider.com/Press+Releases/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html Mon, 10 Aug 2026 07:00:00 -0400 A.36747586 APGE O.00036564 O.56046883 http://www.streetinsider.com/Press+Releases/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html <p align="center"><em>AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide</em></p> <p align="center"><em>Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year</em></p> <p align="justify">SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&amp;I) markets, today reported second http://www.streetinsider.com/Press+Releases/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html Mon, 10 Aug 2026 07:00:00 -0400 A.36747586 APGE O.00036564 O.56046883 http://www.streetinsider.com/Globe+Newswire/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html <p align="center"><em>AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide</em></p> <p align="center"><em>Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year</em></p> <p align="justify">SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&amp;I) markets, today reported second http://www.streetinsider.com/Globe+Newswire/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html Mon, 10 Aug 2026 07:00:00 -0400 A.36747586 APGE O.00036564 O.56046883 http://www.streetinsider.com/Globe+Newswire/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html <p align="center"><em>AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide</em></p> <p align="center"><em>Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year</em></p> <p align="justify">SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&amp;I) markets, today reported second http://www.streetinsider.com/Globe+Newswire/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html Mon, 10 Aug 2026 07:00:00 -0400 A.36747586 APGE O.00036564 O.56046883 http://www.streetinsider.com/Globe+Newswire/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html <p align="center"><em>AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide</em></p> <p align="center"><em>Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year</em></p> <p align="justify">SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&amp;I) markets, today reported second http://www.streetinsider.com/Globe+Newswire/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html Mon, 10 Aug 2026 07:00:00 -0400 A.36747586 APGE O.00036564 O.56046883 http://www.streetinsider.com/Globe+Newswire/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html <p align="center"><em>AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide</em></p> <p align="center"><em>Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year</em></p> <p align="justify">SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&amp;I) markets, today reported second http://www.streetinsider.com/Globe+Newswire/Apogee+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+and+Pipeline+Updates/26894087.html Mon, 10 Aug 2026 07:00:00 -0400 A.36747586 APGE O.00036564 O.56046883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+05++Filed+by%3A+Dambkowski+Carl/26892523.html si-local-file:///var/storage/secattach/20260807/26892523.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+05++Filed+by%3A+Dambkowski+Carl/26892523.html Fri, 07 Aug 2026 20:00:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+05++Filed+by%3A+Dambkowski+Carl/26892523.html si-local-file:///var/storage/secattach/20260807/26892523.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apogee+Therapeutics%2C++++++For%3A+Aug+05++Filed+by%3A+Dambkowski+Carl/26892523.html Fri, 07 Aug 2026 20:00:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Apogee+Therapeutics%2C+++++++++++++++++/26877813.html si-local-file:///var/storage/secattach/20260806/26877813.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Apogee+Therapeutics%2C+++++++++++++++++/26877813.html Thu, 06 Aug 2026 06:31:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Apogee+Therapeutics%2C+++++++++++++++++/26877813.html si-local-file:///var/storage/secattach/20260806/26877813.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Apogee+Therapeutics%2C+++++++++++++++++/26877813.html Thu, 06 Aug 2026 06:31:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Apogee+Therapeutics%2C+++++++++++++++++/26859241.html si-local-file:///var/storage/secattach/20260803/26859241.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Apogee+Therapeutics%2C+++++++++++++++++/26859241.html Mon, 03 Aug 2026 17:10:00 -0400 APGE O.56046883 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Apogee+Therapeutics%2C+++++++++++++++++/26859241.html si-local-file:///var/storage/secattach/20260803/26859241.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Apogee+Therapeutics%2C+++++++++++++++++/26859241.html Mon, 03 Aug 2026 17:10:00 -0400 APGE O.56046883